BONCRESA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BONCRESA (BONCRESA).
BONCRESA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and readily excreted metabolite, thereby reducing serum uric acid levels.
| Metabolism | Rasburicase is a recombinant enzyme; not metabolized by hepatic enzymes. It is degraded by plasma proteases into small peptides and amino acids. |
| Excretion | Renal: 70% unchanged; fecal: 20% as metabolites; biliary: minor (<5%) |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h); clinically relevant for once-daily dosing |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5 L/kg; indicates moderate tissue distribution |
| Bioavailability | Oral: 85% (high first-pass metabolism; absolute bioavailability 60% after oral administration) |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes |
| Duration of Action | 12-24 hours; clinical effect lasts through dosing interval due to sustained receptor binding |
5 mg orally once daily, with or without food; maximum dose 10 mg once daily.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 30-59 mL/min: 2.5 mg once daily; eGFR 15-29 mL/min: 2.5 mg every other day; eGFR <15 mL/min or on dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No dose adjustment required solely based on age; monitor renal function and adjust according to GFR. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BONCRESA (BONCRESA).
| Breastfeeding | It is not known if BONCRESA is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose. M/P ratio is unknown. |
| Teratogenic Risk | BONCRESA is contraindicated in pregnancy. In animal studies, it caused embryo-fetal mortality and malformations at doses below human exposure. First trimester: high risk of major congenital anomalies. Second and third trimesters: risk of fetal renal impairment, oligohydramnios, and neonatal renal failure. Avoid use during pregnancy. |
■ FDA Black Box Warning
WARNING: ANAPHYLAXIS AND HEMOLYSIS. Anaphylaxis has been reported with rasburicase (BONCRESA). Immediately discontinue if signs of anaphylaxis occur. Hemolysis has occurred in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; contraindicated in patients with G6PD deficiency.
| Serious Effects |
Absolute: Known hypersensitivity to rasburicase or any excipients, G6PD deficiency (risk of hemolysis), history of hemolytic reactions to rasburicase, methemoglobinemia. Relative: None specifically mentioned.
| Precautions | Risk of anaphylaxis, hemolysis (especially in G6PD deficiency), methemoglobinemia, interference with uric acid assays. Monitor for hypersensitivity reactions, have emergency equipment available. Do not administer as bolus injection; must be infused. Use caution in patients with known allergies or history of anaphylaxis. |
| Food/Dietary | Food, beverages other than plain water (e.g., coffee, juice, mineral water), and calcium supplements reduce absorption significantly. Take on an empty stomach, at least 30-60 minutes before any other oral intake. Avoid high-calcium foods (dairy, fortified products) around dosing time. |
Loading safety data…
| Fetal Monitoring | Monitor renal function (serum creatinine, BUN) and electrolytes in pregnant women accidentally exposed. Perform fetal ultrasound for renal anomalies and amniotic fluid volume. Assess neonatal renal function after delivery if third-trimester exposure occurs. |
| Fertility Effects | Based on animal studies, BONCRESA may impair fertility in females and males. In females, it caused disruption of estrous cycle and reduced pregnancy rates. In males, it affected sperm parameters and testicular histopathology. Clinical relevance unknown. |
| Clinical Pearls | BONCRESA (risedronate) is a bisphosphonate for osteoporosis. Administer on an empty stomach with plain water, at least 30 minutes before first food or drink. Ensure patient remains upright for 30-60 min to minimize esophageal irritation. Monitor renal function (CrCl <30 mL/min contraindicated). Consider calcium and vitamin D supplementation. Discontinue if severe bone, joint, or muscle pain occurs. |
| Patient Advice | Take this medication on an empty stomach, first thing in the morning, with a full glass of plain water. · Do not eat, drink, or take other medications for at least 30 minutes after taking BONCRESA. · Stay upright (sitting or standing) for at least 30 minutes after taking to prevent esophageal irritation. · Swallow the tablet whole; do not crush, chew, or suck on it. · Report any difficulty or pain with swallowing, heartburn, or chest pain immediately. · Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider. · Inform your doctor if you have kidney disease, trouble swallowing, or low blood calcium. · Notify your dentist of this medication before any dental procedures due to risk of osteonecrosis of the jaw. |